S&P 500   3,957.63
DOW   33,852.53
QQQ   280.57
Three Reasons It’s Time To Get Bullish On Organigram
The 3-Stock Retirement Blueprint (Ad)
The AP Interview: IMF head urges China to end mass lockdowns
Survivor of Virginia Walmart mass shooting files $50M suit
In 20 years, this little-known trader didn’t have a single losing year… (Ad)
Can I Apply for Supplemental Security Income Online?
What an Inverted Yield Curve Means for Investors
“The Bull Market Is Officially OVER”  (Ad)
US stocks edge lower in unsteady trading, oil prices rise
Why Investors Are Eating Up Restaurant Brands International
S&P 500   3,957.63
DOW   33,852.53
QQQ   280.57
Three Reasons It’s Time To Get Bullish On Organigram
The 3-Stock Retirement Blueprint (Ad)
The AP Interview: IMF head urges China to end mass lockdowns
Survivor of Virginia Walmart mass shooting files $50M suit
In 20 years, this little-known trader didn’t have a single losing year… (Ad)
Can I Apply for Supplemental Security Income Online?
What an Inverted Yield Curve Means for Investors
“The Bull Market Is Officially OVER”  (Ad)
US stocks edge lower in unsteady trading, oil prices rise
Why Investors Are Eating Up Restaurant Brands International
S&P 500   3,957.63
DOW   33,852.53
QQQ   280.57
Three Reasons It’s Time To Get Bullish On Organigram
The 3-Stock Retirement Blueprint (Ad)
The AP Interview: IMF head urges China to end mass lockdowns
Survivor of Virginia Walmart mass shooting files $50M suit
In 20 years, this little-known trader didn’t have a single losing year… (Ad)
Can I Apply for Supplemental Security Income Online?
What an Inverted Yield Curve Means for Investors
“The Bull Market Is Officially OVER”  (Ad)
US stocks edge lower in unsteady trading, oil prices rise
Why Investors Are Eating Up Restaurant Brands International
S&P 500   3,957.63
DOW   33,852.53
QQQ   280.57
Three Reasons It’s Time To Get Bullish On Organigram
The 3-Stock Retirement Blueprint (Ad)
The AP Interview: IMF head urges China to end mass lockdowns
Survivor of Virginia Walmart mass shooting files $50M suit
In 20 years, this little-known trader didn’t have a single losing year… (Ad)
Can I Apply for Supplemental Security Income Online?
What an Inverted Yield Curve Means for Investors
“The Bull Market Is Officially OVER”  (Ad)
US stocks edge lower in unsteady trading, oil prices rise
Why Investors Are Eating Up Restaurant Brands International

Novartis - NVS Stock Forecast, Price & News

$87.36
-0.32 (-0.36%)
(As of 11/29/2022 12:00 AM ET)
Add
Compare
Today's Range
$87.28
$88.01
50-Day Range
$74.61
$87.71
52-Week Range
$74.09
$94.26
Volume
1.40 million shs
Average Volume
2.41 million shs
Market Capitalization
$193.29 billion
P/E Ratio
8.98
Dividend Yield
2.46%
Price Target
$85.45

Novartis MarketRank™ Forecast

Analyst Rating
Hold
1.93 Rating Score
Upside/​Downside
2.2% Downside
$85.45 Price Target
Short Interest
Healthy
0.24% of Float Sold Short
Dividend Strength
Moderate
Based on Four Factors
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
6.49%
From $6.01 to $6.40 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.18 out of 5 stars

Medical Sector

519th out of 1,038 stocks

Pharmaceutical Preparations Industry

237th out of 510 stocks

NVS stock logo

About Novartis (NYSE:NVS) Stock

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

Receive NVS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Novartis and its competitors with MarketBeat's FREE daily newsletter.

NVS Stock News Headlines

Novartis (NVS) Set to Advance Malaria Drug Into Phase III
Millionaire Investor Reveals: “How I Made My Second Fortune… By Avoiding 99% of Stocks”
Buy this small group of unique stocks… never sell them… and make all the money you need… No matter what happens in the market. Revealed here: the name and ticker of the #1 stock. pixel
Novartis shifting all gene therapy production to Durham
Novartis AG (NVS) Q3 2022 Earnings Call Transcript
Millionaire Investor Reveals: “How I Made My Second Fortune… By Avoiding 99% of Stocks”
Buy this small group of unique stocks… never sell them… and make all the money you need… No matter what happens in the market. Revealed here: the name and ticker of the #1 stock. pixel
Novartis Whale Trades For October 24
Recap: Novartis Q3 Earnings
Novartis: Healthy Results
Novartis (NVS) Q3 Earnings Top, Revenues Miss Estimates
Novartis (NVS) Q3 2022 Earnings Call Transcript
What's in Store for Novartis (NVS) This Earnings Season?
Novartis' (NVS) Pluvicto Secures Positive CHMP Opinion
Novartis (NVS) Stock Moves -0.58%: What You Should Know
See More Headlines
Receive NVS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Novartis and its competitors with MarketBeat's FREE daily newsletter.

NVS Company Calendar

Last Earnings
10/25/2022
Today
11/29/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
2/01/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Employees
104,323
Year Founded
1996

Price Target and Rating

Average Stock Price Forecast
$85.45
High Stock Price Forecast
$105.00
Low Stock Price Forecast
$70.00
Forecasted Upside/Downside
-2.2%
Consensus Rating
Hold
Rating Score (0-4)
1.93
Research Coverage
15 Analysts

Profitability

Net Income
$24.02 billion
Pretax Margin
46.16%

Debt

Sales & Book Value

Annual Sales
$51.63 billion
Cash Flow
$8.98 per share
Book Value
$30.32 per share

Miscellaneous

Outstanding Shares
2,212,600,000
Free Float
2,212,379,000
Market Cap
$193.29 billion
Optionable
Optionable
Beta
0.55

Social Links


Key Executives

  • Dr. Vasant Narasimhan (Age 46)
    Chief Exec. Officer
    Comp: $5.11M
  • Mr. Harry Kirsch (Age 57)
    Chief Financial Officer
    Comp: $2.84M
  • Dr. Klaus Moosmayer Ph.D. (Age 54)
    Chief Ethics, Risk & Compliance Officer
    Comp: $1.39M
  • Ms. Karen L. Hale (Age 54)
    Chief Legal Officer
    Comp: $2.08M
  • Dr. Robert Kowalski Pharm.D. (Age 54)
    Chief People & Organization Officer
    Comp: $1.2M
  • Mr. Steffen Lang Ph.D. (Age 55)
    Pres of Operations
    Comp: $2.36M
  • Ms. Marie-France Tschudin (Age 51)
    Pres of Innovative Medicines International & Chief Commercial Officer
    Comp: $2.58M
  • Mr. Richard Saynor (Age 55)
    Chief Exec. Officer of Sandoz
    Comp: $1.87M
  • Paul Penepent
    Head of Group Financial Reporting and Accounting
  • Dr. Samir Shah M.D.
    Global Head of Investor Relations













NVS Stock - Frequently Asked Questions

Should I buy or sell Novartis stock right now?

15 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Novartis in the last twelve months. There are currently 3 sell ratings, 10 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" NVS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NVS, but not buy additional shares or sell existing shares.
View NVS analyst ratings
or view top-rated stocks.

What is Novartis' stock price forecast for 2023?

15 brokerages have issued 12 month price objectives for Novartis' shares. Their NVS share price forecasts range from $70.00 to $105.00. On average, they anticipate the company's stock price to reach $85.45 in the next year. This suggests that the stock has a possible downside of 2.2%.
View analysts price targets for NVS
or view top-rated stocks among Wall Street analysts.

How have NVS shares performed in 2022?

Novartis' stock was trading at $87.47 at the beginning of the year. Since then, NVS stock has decreased by 0.1% and is now trading at $87.39.
View the best growth stocks for 2022 here
.

When is Novartis' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 1st 2023.
View our NVS earnings forecast
.

How were Novartis' earnings last quarter?

Novartis AG (NYSE:NVS) announced its quarterly earnings data on Tuesday, October, 25th. The company reported $1.58 EPS for the quarter, topping analysts' consensus estimates of $1.57 by $0.01. The business had revenue of $12.54 billion for the quarter, compared to analysts' expectations of $12.90 billion. Novartis had a net margin of 42.66% and a trailing twelve-month return on equity of 20.89%.

How often does Novartis pay dividends? What is the dividend yield for Novartis?

Novartis announced an annual dividend on Thursday, February 3rd. Stockholders of record on Wednesday, March 9th will be paid a dividend of $1.175 per share on Thursday, March 17th. This represents a yield of 1.36%. The ex-dividend date is Tuesday, March 8th.
Read our dividend analysis for NVS
.

Is Novartis a good dividend stock?

Novartis (NYSE:NVS) pays an annual dividend of $2.16 per share and currently has a dividend yield of 2.46%. The company has been increasing its dividend for 3 consecutive year(s), indicating that it does not yet have a strong track record of dividend growth. The dividend payout ratio is 22.20%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, NVS will have a dividend payout ratio of 33.75% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for NVS.

What is Vas Narasimhan's approval rating as Novartis' CEO?

938 employees have rated Novartis Chief Executive Officer Vas Narasimhan on Glassdoor.com. Vas Narasimhan has an approval rating of 95% among the company's employees. This puts Vas Narasimhan in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Novartis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Novartis investors own include Johnson & Johnson (JNJ), Pfizer (PFE), AbbVie (ABBV), Intel (INTC), AT&T (T), Walt Disney (DIS), Gilead Sciences (GILD), Cisco Systems (CSCO), Merck & Co., Inc. (MRK) and NVIDIA (NVDA).

What is Novartis' stock symbol?

Novartis trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVS."

Who are Novartis' major shareholders?

Novartis' stock is owned by many different institutional and retail investors. Top institutional shareholders include Primecap Management Co. CA (0.79%), Dimensional Fund Advisors LP (0.29%), Cullen Capital Management LLC (0.16%), Renaissance Technologies LLC (0.14%), Two Sigma Advisers LP (0.11%) and State Street Corp (0.09%).

How do I buy shares of Novartis?

Shares of NVS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Novartis' stock price today?

One share of NVS stock can currently be purchased for approximately $87.39.

How much money does Novartis make?

Novartis (NYSE:NVS) has a market capitalization of $193.36 billion and generates $51.63 billion in revenue each year. The company earns $24.02 billion in net income (profit) each year or $9.73 on an earnings per share basis.

How many employees does Novartis have?

The company employs 104,323 workers across the globe.

Does Novartis have any subsidiaries?
The following companies are subsidiares of Novartis: 1 A Pharma GmbH, Abadia Retuerta S.A, Admune Therapeutics, Advanced Accelerator Applications, Advanced Accelerator Applications, Advanced Accelerator Applications International SA, Advanced Accelerator Applications S.A., Advanced Accelerator Applications S.r.l., Advanced Accelerator Applications USA Inc., Aeropharm GmbH, Alcon, Alcon – Couvreur NV, Amblyotech, Amblyotech Inc., Arctos Medical, Arctos Medical AG, Australia Pty Ltd, Beijing Novartis Pharma Co. Ltd., BioMedical Research Co. Ltd., CELLforCURE, Cadent Therapeutics, Cadent Therapeutics Cambridge, Cellerys, Cellerys AG, CellforCure, Chiron Corporation, Ciba-Geigy Japan Limited, Co. Ltd, CoStim Pharmaceuticals, CoStim Pharmaceuticals Inc., Coalesce Product Development Limited, Corthera, Development Co. Ltd., EBEWE Pharma Ges.m.b.H Nfg. KG, Encore Vision, Endocyte, Endocyte Inc., Eon Labs Inc., Farmanova Saglik Hizmetleri Ltd, Fougera Pharmaceuticals, Fougera Pharmaceuticals Inc, Gyroscope Therapeutics, HEXAL AG, Hexal, IDB Holland BV, Iberica S.L.U., Ilaçlari Sanayi ve Ticaret A.S, JSC Sandoz, Japat AG, Kedalion Therapeutics Inc., Lek Pharmaceuticals d.d., Lek S.A., Manufacturing Pte Ltd , Navigate BioPharma Services Inc, Neutec Pharma Limited, Novartis (Hellas) S.A.C.I., Novartis (Singapore) Pte Ltd, Novartis (Taiwan) Co. Ltd, Novartis (Thailand) Limited, Novartis Argentina S.A., Novartis Australia Pty Ltd, Novartis Austria GmbH, Novartis Biociências S.A., Novartis Biosciences Perú S.A., Novartis Bioventures AG, Novartis Business Services GmbH, Novartis Capital Corporation, Novartis Chile S.A., Novartis Corporation, Novartis Corporation Sdn. Bhd., Novartis Deutschland GmbH, Novartis Ecuador S.A., Novartis Farma S.p.A., Novartis Farma – Produtos Farmacêuticos S.A., Novartis Farmacéutica S.A, Novartis Farmacéutica S.A. de C.V., Novartis Finance Corporation, Novartis Finance S.A., Novartis Finance Services Ltd, Novartis Finland Oy Espoo, Novartis Gene Therapies, Novartis Gene Therapies EU Limited, Novartis Gene Therapies Inc., Novartis Grimsby Limited, Novartis Groupe France S.A., Novartis Healthcare A/S, Novartis Healthcare Philippines Inc., Novartis Healthcare Private Limited, Novartis Holding AG, Novartis Hungary Healthcare Limited Liability Company, Novartis India Limited, Novartis Inflammasome Research, Novartis Integrated Services Limited, Novartis International AG, Novartis International Pharmaceutical Investment AG, Novartis Investment Ltd, Novartis Investments S.à r.l., Novartis Ireland Limited, Novartis Israel Ltd, Novartis Korea Ltd., Novartis Middle East FZE, Novartis Netherlands B.V., Novartis Neva LLC, Novartis New Zealand Ltd, Novartis Norge AS, Novartis Ophthalmics AG, Novartis Optogenetics Research Inc., Novartis Overseas Investments AG, Novartis Pharma (Logistics) Inc., Novartis Pharma (Pakistan) Limited, Novartis Pharma AG, Novartis Pharma B.V. , Novartis Pharma GmbH, Novartis Pharma GmbH, Novartis Pharma K.K., Novartis Pharma LLC, Novartis Pharma Maroc SA, Novartis Pharma NV, Novartis Pharma Produktions GmbH, Novartis Pharma S.A.E., Novartis Pharma S.A.S., Novartis Pharma Schweiz AG, Novartis Pharma Schweizerhalle AG, Novartis Pharma Services AG, Novartis Pharma Services Romania S.R.L., Novartis Pharma Stein AG, Novartis Pharmaceuticals Canada Inc., Novartis Pharmaceuticals Corporation, Novartis Pharmaceuticals Limited, Novartis Pharmaceuticals UK Limited, Novartis Poland Sp. z o.o., Novartis Portugal S.G.P.S. Lda., Novartis Ringaskiddy Limited, Novartis Saglik Gida ve Tarim Ürünleri Sanayi ve Ticaret A.S, Novartis Saudi Ltd., Novartis Securities Investment Ltd, Novartis Services Inc., Novartis Slovakia s.r.o., Novartis South Africa (Pty) Ltd, Novartis Sverige AB, Novartis UK Limited, Novartis US Foundation, Novartis Vaccines and Diagnostics Inc, Novartis Vietnam Company Limited, Novartis de Colombia S.A., Novartis de Venezuela S.A., Novartis s.r.o., Oriel Therapeutics Inc., PT. Novartis Indonesia, Protez Pharmaceuticals, Pte Ltd, Research Inc, Salutas Pharma GmbH, Sandoz A/S, Sandoz AG, Sandoz B.V., Sandoz Canada Inc., Sandoz Egypt Pharma S.A.E., Sandoz Farmacéutica S.A., Sandoz Farmacêutica Lda., Sandoz GmbH, Sandoz Hungary Limited Liability Company, Sandoz Ilaç Sanayi ve Ticaret A.S., Sandoz Inc, Sandoz Industrial Products S.A, Sandoz International GmbH, Sandoz K.K., Sandoz Limited, Sandoz Manufacturing Inc., Sandoz NV, Sandoz Pharma K.K, Sandoz Pharmaceuticals AG, Sandoz Pharmaceuticals d.d., Sandoz Philippines Corporation, Sandoz Polska Sp. z o.o. , Sandoz Private Limited, Sandoz Pty Ltd, Sandoz S.A. de C.V, Sandoz S.A.S., Sandoz S.R.L., Sandoz S.p.A., Sandoz South Africa (Pty) Ltd, Sandoz Ukraine LLC, Sandoz d.o.o. farmaceutska industrija, Sandoz do Brasil Indústria Farmacêutica Ltda, Sandoz s.r.o., Selexys Pharmaceuticals Corporation, Shanghai Novartis Trading Ltd., Société par actions SANDOZ, Spinifex Pharmaceuticals, The Medicines Company, The Medicines Company, Triangle International Reinsurance Limited, Trinity River Insurance Co Ltd, Vedere Bio, Vedere Bio ll, Xiidra, Ziarco, and Ziarco Group Limited.
Read More
How can I contact Novartis?

Novartis' mailing address is LICHTSTRASSE 35, BASEL V8, CH 4056. The official website for the company is www.novartis.com. The company can be reached via phone at (161) 324-1111, via email at investor.relations@novartis.com, or via fax at 41-61-324-7826.

This page (NYSE:NVS) was last updated on 11/30/2022 by MarketBeat.com Staff